Mission

To develop precision medicines that target hypoxic (low oxygen) areas
in tumours that conventional chemotherapy, immunotherapy and radiotherapy
do not treat  hypoxia is recognized as a key pan-cancer resistance mechanism.

OncoTherics Technology
unidirectional Hypoxia Activated Prodrugs (uHAPs)

HYPOXIC CANCER CELLS
THE PROBLEM
HYPOXIC CANCER CELLS
CONVENTIONAL THERAPIES
DO NOT TREAT HYPOXIA
uHAPs REACH
HYPOXIC CANCER CELLS
uHAPs KILL
HYPOXIC CANCER CELLS

Read more about our research

Find out more...

Team
About us
Read more
science
Science
Read more

Pipeline

uHAP’s: a tumour agnostic therapy 2 lead assets, at different phases of development

  • 2 lead assets, at different phases of development
  • uHAP 1: extensive Phase I experience, excellent safety profile
  • uHAP 2: second generation molecule - broad applications in many tumours

The uHAP Competitive Advantage

Non-Cytotoxic Prodrugs

minimal effects compared to conventional cytotoxics

Excellent Penetration

across all tissues, crosses the blood brain barrier

Irreversible

effective, persistent TOPO 2 Inhibitors at target hypoxic sites

Read more

Contact

OncoTherics Poland Sp. z o.o.
ul. prof. Michała Bobrzyńskiego 14
30-348 Kraków
Poland

Copyright © 2010 - 2020 All rights reserved